Related Experiment Videos
Glycerol for acute ischaemic stroke.
1Department of Neurology, University of Copenhagen, Bispebjerg Hospital, Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark. gb01@bbh.hosp.dk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Intravenous glycerol may reduce early deaths in acute ischemic stroke patients. However, more research is needed to confirm its effectiveness and safety for stroke treatment.
Area of Science:
- Neurology
- Clinical Trials
- Pharmacology
Background:
- Ischemic stroke-related edema is a significant cause of early mortality.
- Intravenous glycerol shows potential in reducing edema, enhancing cerebral blood flow, and improving metabolism.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of glycerol in treating acute ischemic stroke.
Main Methods:
- Conducted a systematic review of randomized controlled trials comparing intravenous glycerol with control in acute ischemic stroke patients.
- Included trials where glycerol treatment commenced within four days of stroke onset.
- Assessed trial quality and extracted data independently.
Main Results:
- Eight trials with 649 participants were analyzed.
- Glycerol showed a significant reduction in 14-day mortality (OR 0.58, 95% CI 0.36-0.91).
- No significant reduction in one-year mortality was observed (OR 0.82, 95% CI 0.54-1.23). Hemolysis was the sole reported adverse effect.
Conclusions:
- Current evidence is insufficient to definitively evaluate glycerol's role in acute ischemic stroke management.
- Further high-quality trials are necessary to establish its clinical utility and safety profile.